Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[AndreasP]

Er det sannsynlig med LYMRIT 37-01 DOR read out på årets Lugano event ( ICML International Conference on Malignant Lymphoma)??

• Submission of abstracts for oral presentations (general sessions and “Focus on…” sessions) and poster presentation closed on Friday, March 15, 2019, 17:59 CET .
• Notification regarding abstract evaluation results (acceptance for oral or poster presentation, inclusion in the Abstract Book or rejection) will be sent to the first author/presenter by Friday, May 3, 2019.

[TekBot]

28/03-2019 08:00:09: (NANO) Nordic Nanovector to present at DNB’s SME conference and Kempen Life Science conference

Oslo, Norway, 28 March 2019

Nordic Nanovector ASA (OSE: NANO) announces that members of its senior
…

Vis børsmeldingen

management team will participate and present at the following upcoming investor
conferences during April:

· DNB’s 15th Annual Small & Medium Enterprises (SME) Conference in Oslo on 4
April
· The 12th Kempen Life Sciences Conference in Amsterdam on 16-17 April

The company presentation will be available on the investors and media page on
the first day of the conference.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190328.OBI.20190328S11

[pdx]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (905 likes)

Ble akkurat postet et papir på twitter som jeg ikke har sett før, hvor Dr Zinsani er en av forfatterene.

2. @studenten86 (591 likes)

Nordic Nanovector Aksjonærlister og Shortaktører (NANO)

3. @TyrionIV (385 likes)

Har lagd en liten oppsummering av salget til Lutathera og sammenligningen med Betalutin som jeg hadde tidligere i uka over flere innlegg på småprat-tråden siden dette gav meg veldig gode vibber ift de nærmeste 2-3 årene.

Resten av topp 10:

4. @anon21766851 (357 likes)

5. @Nocturne (238 likes)

6. @vegar_beider (199 likes)

7. @InVivo (194 likes)

8. @Oilimp (192 likes)

9. @Fornybar (174 likes)

10. @Krieghoff (170 likes)

Gratulerer!

[studenten86]

Med emisjonen i siste kvartal og short-eskaleringen vi så på starten av året har det vært et kjipt kvartal.
Oppdatering på siste 3 mnd:

• 74 Klinikker som rekrutterer til Paradigme. Optimistiske anslag før denne oppdateringa spådde 65+. Det er 23 forskjellige land av forespeilet ‘rundt 20’ som rekrutterer til Paradigme.
• Klinikker i Asia åpen er en liten joker.
• Emisjonen, vond som den var, tilførte selskapet en kvart milliard kroner i kassa(når du tar med rep emi). Rett i underkant av 3 kvartaler ekstra drift er vel konsensus om dagen.

Kursutviklingen siste kvartal

Short presset på i januar, og fortsatte med emi nyheter. Siden den gang har det vært svakt stigende, men selskapet har per nå falt i markedsverdi med en styrket kapital-posisjon og meget positiv oppdatering fra rekrutteringsfronten.
Det sagt, så var ikke 51 en spesielt hyggelig pris i seg selv.

Siste kvartal har medført ytterligere rabatt, på en styrket fundamental situasjon, for et selskap som var svært rimelig i utgangspunktet.

[TekBot]

02/04-2019 07:00:00: (NANO, NANOO.ST) Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours presented at TAT11

Oslo, Norway, 2 April 2019

Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral presentation at TAT11, the 11th International Symposium on Targeted-Alpha-Therapy (1-4 April, Ottawa, Canada).
…

Vis børsmeldingen

The research collaboration with Orano Med (formerly known as AREVA Med) was established in June 2016 to develop and investigate a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) and the alpha-particle-generator lead-212 (212Pb) for the treatment of B-cell malignancies.

The results reported in an oral presentation given today describe promising findings from preclinical studies investigating the tolerability and dose-dependent efficacy of 212Pb-NNV003 in mouse models of chronic lymphocytic leukaemia (CLL) and Burkitt’s lymphoma (a type of non-Hodgkin’s lymphoma, NHL).

In the studies, 212Pb-NNV003 displayed a favourable toxicity profile after a single intravenous injection. In one study, 100% of mice with tumour xenografts were alive five months after the injection of 212Pb-NNV003, while only 50% of control mice receiving cold antibody where alive after 1.5 months.

Jostein Dahle, Chief Scientific Officer of Nordic Nanovector, said: “Our research collaboration with Orano Med continues to produce promising preclinical results and provides an early demonstration of the potential of 212Pb-conjugated CD37-targeted alpha therapy to treat leukaemias and lymphomas where there is no substantial tumour mass and tumour cells are near healthy tissues. This approach also may prove useful for CLL and NHL patients who have relapsed or become refractory to standard CD20-targeting agents that are used in front-line therapy. We look forward to further results from this research programme.”

The oral presentation entitled 212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukaemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) was given by Dr A. Saidi of Orano Med.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

 

http://www.netfonds.no/quotes/release.php?id=20190402.Cision.20190401:BIT:6510:0

[dr.Stockman]

I en av studiene var 100% i live etter 5 mndr mens kun 50% var i live etter 1,5 mndr av de ubehandlede. Må vel gange tallene på ti omsatt til menneskeår, så dette er selvfølgelig svært lovende resultater. Et bevis på at NANOs portefølje stadig kan utvides.

[Tixis]

En gjennomsnittelig mus lever i 30 mnd. 5 mnd er 16% av musens liv. Sier vi at snittalder på mennesker er 75 så gir d 12 år

[TekBot]

03/04-2019 20:11:32: (NANO, NANOO.ST) Nordic Nanovector ASA publishes 2018 Annual Report

Oslo, Norway, 3 April 2019

Nordic Nanovector ASA has today published its 2018 Annual Report, including the complete 2018 Annual Accounts with notes. This report is attached to this announcement and available on Nordic Nanovector ASA’s website: www.nordicnanovector.com.
…

Vis børsmeldingen

For further information, please contact: 

IR enquiries  

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries  

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector  

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com 

Forward-looking statements  

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act. 

 

http://www.netfonds.no/quotes/release.php?id=20190403.Cision.20190403:BIT:8645:0

[F-Tosca]

Her er årsrapporten

afcf5daa2c5ad07d.pdf

[TekBot]

04/04-2019 08:38:12: (NANO, NANOO.ST) Nordic Nanovector ASA: Notice of Annual General Meeting on 25 April 2019

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 25 April 2019 at 15.00 hours CEST at Thon Hotel Vika Atrium, Munkedamsveien 45 in Oslo. The full notice with appendices and the recommendation from the Nomination Committee are attached. The notice and the documents to which it refers are also available on www.nordicnanovector.com.

Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea Bank Abp, Issuer Service, Postboks 1166 Sentrum, N-0107 Oslo, or by email to [email protected] no later than 23 April 2019, 16:00 CEST.
…

Vis børsmeldingen

For further information, please contact: 

IR enquiries  

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries  

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector  

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com 

Forward-looking statements  

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act. 

 

http://www.netfonds.no/quotes/release.php?id=20190404.Cision.20190404:BIT:9029:0

[TekBot]

10/04-2019 07:00:13: (NANO) Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

Oslo, Norway, 10 April 2019

Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee
…

Vis børsmeldingen

(SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration
Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation
(SCT) has now reviewed safety data from the first three cohorts of patients.
Based on the data, the SRC approved advancing the trial to the next and final
cohort with the dose regimen 20 MBq/kg Betalutin and a lilotomab pre-dose of 100
mg/m2.

The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation
study designed to assess the safety, tolerability, pharmacokinetic profile and
preliminary anti-tumour activity of Betalutin®. Up to 24 patients are planned to
be enrolled in the US and Europe in total. More information on this study can be
found at www.clinicaltrials.gov (NCT02658968). Preliminary results are expected
in the second half of 2019.

Lisa Rojkjaer, Chief Medical Officer of Nordic Nanovector, commented: “We are
pleased to be moving ahead with the final cohort of patients in the study, which
will enable the selection of a recommended dose for further evaluation of safety
and preliminary efficacy in additional patients.”

DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for up
to 43% of all NHL cases, making it the most common form of the disease.
Approximately 40% of DLBCL patients relapse after first-line combination
treatment with rituximab and chemotherapy and only 30-40% of relapsed patients
respond with subsequent high-dose chemotherapy followed by SCT (ref. 1). There
are currently very few therapeutic options for patients not eligible for SCT,
which makes relapsed DLBCL a serious unmet medical need. The number of diagnosed
cases of DLBCL in the US and Europe in 2016 was 26,500 and 17,200, respectively.
These numbers are expected to reach 31,500 (US) and 19,000 (Europe) by 2024
(ref. 2).

References

1. L.S. Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse
   large B cell lymphoma (2014) South Asian J. Cancer 3(1): 66-70

2. Non-Hodgkin’s Lymphoma (2015) Decision Resources

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190410.OBI.20190410S6

[anon21766851]

Bra med fremgang. Bare å pumpe på nå da. Stusser dog litt, for var det ikke guidet å ha siste pasient i 37-05 behandlet i løpet av 1h? Begynner å bli travelt🤔

[Savepig]

Første som slo meg og, blir garantert et tema på q1 rapporten

[Krieghoff]

Er jo open lable og de gjentar at data kommer i H219.

[Fornybar]

Up to 24 patients are planned to
be enrolled

Hvis de har kjørt doseeskalering til nå med 3+3+3 pasienter så ser jeg ikke på det som særlig urimelig at de kan si seg fornøyde med f.eks 9 pasienter med 20/100 den 30 juni.

[JustinBibel]

Stusser dog litt, for var det ikke guidet å ha siste pasient i 37-05 behandlet i løpet av 1h?

Jo, det stemmer - og det henger på greip med det de skriver i børsmeldingen.

Preliminary results are expected in the second half of 2019.

Dette går som tidligere beskrevet: We Are On Track.

[frogjo]

Mr Bravo var ivrig med å trekke frem DLBCL
da han kom i sjefsstolen…han hadde nok gode grunner…de sitter jo med resultater fra de første cohortene…dette lukter d fugl av

[kanon]

Interessant at de kjører kun 20/100.

Dette er jo en indikasjon med mange flere pasienter, så det bør være mulig å rekruttere fortere.

Når kan vi forvente safety ok archer?

[sparkonge]

Virker ikke som alle har studieoppsettet for Lymrit 37-05 (Betalutin for DLBCL) klart for seg: